Lean Insulin Resistance: Why Normal-Weight Individuals Develop Type 2 Diabetes

When most people picture type 2 diabetes or insulin resistance, they imagine an individual with obvious excess weight. Conventional medical teaching has long reinforced this view, tying metabolic risk directly to an elevated Body Mass Index (BMI).

However, metabolic dysfunction does not always present as outward obesity.

In clinical practice, a significant subset of individuals develop severe insulin resistance, elevated fasting triglycerides, hepatic steatosis (fatty liver), and HbA1c levels in the diabetic range despite maintaining a normal BMI.

Often referred to in medical literature as Metabolically Obese Normal-Weight (MONW) or lean insulin resistance, this phenotype is frequently overlooked until significant metabolic damage has already occurred [1].

Understanding lean insulin resistance requires looking beyond the bathroom scale. Here is an evidence-based breakdown of why lean individuals develop diabetes, the genetics behind adipose storage limits, why this phenotype is particularly prevalent in South and Southeast Asian populations, and how lifestyle and medical treatments must be tailored accordingly.

1. The Asian Phenotype: Why Standard BMI Misses Metabolic Risk

The relationship between body weight, body fat distribution, and metabolic risk varies considerably by genetic ancestry [2].

Epidemiological cohorts demonstrate that individuals of South Asian (Indian, Pakistani, Bangladeshi) and Southeast/East Asian descent develop insulin resistance and type 2 diabetes at substantially lower BMI thresholds and younger ages compared to individuals of European descent [2, 3].

This presentation, often termed the "South Asian Phenotype," is characterized by [2, 3]:

• Lower baseline skeletal muscle mass.

• A higher percentage of total body fat at any given BMI.

• A pronounced tendency to store lipids as visceral and ectopic fat (fat deposited in and around abdominal organs) rather than in safe subcutaneous compartments [2, 3].

Because standard BMI classifications were historically derived from predominantly White European populations, they underestimate cardiometabolic risk in Asian populations.

To address this, organizations including the World Health Organization (WHO) and the American Diabetes Association (ADA) established ethnicity-specific BMI cutoffs for Asian adults [3]:

• Normal Weight: 18.5 to 22.9 kg/m2

• Overweight / Increased Risk: 23.0 to 27.4 kg/m2

• Obesity / High Risk: >= 27.5 kg/m2 (with some regional guidelines defining obesity at >= 25.0 kg/m2)

Under these criteria, an Asian individual with a BMI of 23 kg/m2 may carry the same visceral fat burden, hepatic insulin resistance, and cardiovascular risk as a Caucasian individual with a BMI of 30 kg/m2 [2, 3].

2. The Pathophysiology: Adipose Expandability and Ectopic Lipid Spillover

Why does a lean individual develop high blood sugar?

The primary mechanism is explained by the Adipose Tissue Expandability Hypothesis and the concept of the Personal Fat Threshold (PFT) [4, 5].

1. Subcutaneous Storage Limits: Subcutaneous adipose tissue (the fat layer beneath the skin) serves as the body’s safe metabolic storage buffer. Every person has a genetically determined capacity for how much subcutaneous fat they can store. In lean individuals prone to diabetes, this storage capacity is relatively small [4].

2. Lipid Spillover: When energy intake exceeds an individual's personal threshold—even by modest amounts—subcutaneous fat depots cannot expand further. Excess lipids spill over into the bloodstream as elevated free fatty acids and triglycerides [4].

3. Ectopic Fat in the Liver: Excess lipids deposit directly inside liver cells (hepatic steatosis / MASLD), causing hepatic insulin resistance. The liver loses its sensitivity to insulin and continues to release glucose into the blood even during fasting states [5].

4. Ectopic Fat in Skeletal Muscle: Lipids deposit within muscle tissue (intramyocellular fat), interfering with insulin-signaling pathways and impairing post-meal glucose uptake [4].

5. Pancreatic Beta-Cell Lipotoxicity: Ectopic fat accumulates in the pancreas, impairing insulin secretion and driving blood sugar into the diabetic range [5].

Landmark clinical research (such as the ReTUNE trial) has confirmed that even in normal-weight individuals with type 2 diabetes (BMI 21 to 27 kg/m2), modest, targeted weight loss of roughly 5% to 7% can reverse ectopic fat in the liver and pancreas, restoring normal beta-cell function and leading to diabetes remission [5].

3. Tailored Lifestyle Strategies: Protecting Muscle While Clearing Ectopic Fat

For an individual with significant excess weight, the primary objective is creating a substantial caloric deficit to reduce overall fat mass.

In lean individuals, however, unguided severe caloric restriction carries a major risk: the loss of skeletal muscle mass.

Because skeletal muscle is the primary tissue responsible for clearing glucose from the bloodstream after meals, losing muscle shrinks the body's main glucose disposal sink [6].

A lifestyle protocol for lean insulin resistance must balance clearing ectopic organ fat while preserving or building skeletal muscle:

• Prioritize Progressive Resistance Training: Strength training is the foundation of management. Muscle contraction stimulates glucose transporter (GLUT4) translocation to cell membranes independently of insulin, providing direct blood sugar clearance while expanding overall glucose storage capacity [6].

• Adequate Protein Intake: Consuming 1.6 to 2.2 grams of protein per kilogram of body weight supports muscle protein synthesis and recovery, ensuring that any weight management efforts spare lean tissue.

• Carbohydrate Quality Over Extreme Restriction: Rather than eliminating all carbohydrates, focus on minimizing refined sugars, sweetened beverages, and ultra-processed grains that cause rapid glycemic spikes. Emphasize fiber-rich, intact carbohydrates (legumes, vegetables, whole grains) paired with protein and healthy fats.

• Aerobic Base Conditioning: Low-to-moderate intensity aerobic exercise improves mitochondrial density and enhances the oxidative capacity of skeletal muscle, assisting in the clearance of intramyocellular lipids [6].

4. Medical Therapies and Pharmaceutical Nuance

Pharmacological management in lean insulin-resistant patients requires choosing agents that improve insulin sensitivity and glycemic control without exacerbating muscle loss:

The Role of GLP-1 Receptor Agonists

GLP-1 receptor agonists (such as semaglutide and tirzepatide) are highly effective at lowering blood glucose and reducing ectopic liver fat. However, because these medications produce weight loss that typically includes a proportion of fat-free mass (often around 20% to 30% of total weight lost, comparable to standard dietary restriction), their use in normal-weight individuals requires caution.

In someone who is already lean with low baseline muscle mass, further unmonitored muscle loss can compromise functional capacity. When incretin-based therapies are used in normal-weight or borderline-weight patients with diabetes, concurrent high-protein nutrition and progressive resistance training are critical to maintain lean mass.

Other Targeted Pharmacological Options

• Metformin: First-line therapy that suppresses excess hepatic glucose production and improves peripheral insulin sensitivity without causing significant weight loss or muscle wasting [1].

• Thiazolidinediones (TZDs / Pioglitazone): Mechanistically targeted for adipose expandability limits. As a PPAR-gamma agonist, pioglitazone stimulates the recruitment of new subcutaneous adipocytes, helping to draw toxic ectopic lipids out of the liver, pancreas, and muscle and store them safely beneath the skin [4]. While effective at improving insulin sensitivity, clinicians must monitor for known side effects such as fluid retention.

• SGLT2 Inhibitors: Excrete excess glucose through the urine to reduce glucotoxicity, though hydration and body composition should be monitored in lean patients.

• Acarbose (Alpha-Glucosidase Inhibitors): Delays carbohydrate digestion in the gut, blunting postprandial glucose spikes without affecting systemic weight or muscle mass.

The Bottom Line

A normal BMI is not proof of optimal metabolic health [1, 2].

If your personal capacity to store subcutaneous fat is limited, excess calories spill over into your liver, muscle, and pancreas, driving insulin resistance and type 2 diabetes even in an outwardly lean frame [4, 5].

Addressing lean insulin resistance requires expanding and protecting your metabolic reserves: building skeletal muscle through resistance training, prioritizing protein intake, reducing refined carbohydrates, and choosing medical therapies that preserve lean mass [4, 6].

Track your personal metabolic, cardiovascular, and body composition markers using our free Healthspan Engine.

Have questions about interpreting your fasting insulin, navigating lean diabetes, or personalizing your preventive health strategy? Ask our physicians directly through our Weekly Healthspan Q&A—we answer reader-submitted questions every week in our newsletter.

(Disclosure: The Healthspan Engine and Weekly Q&A are free educational resources provided by delaeMD.)

References

1. Stefan N, Schick F, Häring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metabolism. 2017;26(2):292-300.

2. Misra A, Sattar N, Ghosh A, et al. Type 2 Diabetes in South Asians. BMJ. 2025;390:e079801.

3. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-Specific BMI Cutoffs for Obesity Based on Type 2 Diabetes Risk in England: A Population-Based Cohort Study. The Lancet Diabetes & Endocrinology. 2021;9(7):419-426.

4. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—an allostatic perspective. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2010;1801(3):338-349.

5. Taylor R, Barnes AC, Hollingsworth KG, et al. Aetiology of Type 2 Diabetes in People With a 'Normal' Body Mass Index: Testing the Personal Fat Threshold Hypothesis. Clinical Science. 2023;137(16):1333-1346.

6. Kanaley JA, Colberg SR, Corcoran MH, et al. Exercise/Physical Activity in Individuals With Type 2 Diabetes: A Consensus Statement From the American College of Sports Medicine. Medicine and Science in Sports and Exercise. 2022;54(2):353-368.

7. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367.